Complications | ALD n (%) | HBV n (%) | HCV n (%) | ALD + HBV n (%) | ALD + HCV n (%) | P value |
---|
HCC | 170 (10.3) | 7622 (42.2)a | 142 (20.8)a,b,d | 832 (52.2)a,b | 96 (34.3)a,c,d | < 0.001 |
Infection | 553 (33.5) | 4184 (23.1)a | 129 (18.9)a,d | 486 (30.5)b | 79 (28.2)c | < 0.001 |
Ascites | 892 (54.0) | 7835 (43.3)a | 252 (37.0)a,b,d | 879 (55.1)b | 144 (51.4)c | < 0.001 |
HE | 127 (7.7) | 947 (5.2)a | 20 (2.9)a,d | 104 (6.5) | 14 (5.0) | < 0.001 |
Thrombus | 102 (6.2) | 1040 (5.8) | 35 (5.1) | 80 (5.0) | 12 (4.3) | 0.461 |
EGV† | 813 (49.6) | 6612 (38.3)a | 266 (41.1)b | 707 (45.5)a,b | 129 (46.1)b | 0.001 |
EGVB‡ | 318 (39.1) | 1990 (30.1)a | 87 (32.7) | 306 (43.3)b | 66 (51.2)c | < 0.001 |
HRS | 49 (3.0) | 276 (1.5)a | 8 (1.2) | 35 (2.2) | 3 (1.1) | < 0.001 |
- HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; EGV, esophageal gastric varices; EGVB, esophageal gastric variceal bleeding, HRS, hepatorenal syndrome
- aMeans value statistically significant compared to that in ALD; bmeans value statistically significant compared to that in HBV; cmeans value statistically significant compared to that in HCV; dmeans value statistically significant compared to that in HBV + ALD. Bonferroni correction was used for “P” during pairwise comparisons
- †The proportion of EGV was calculated by dividing the number of patients reported with EGV by the number of patients who underwent upper GI endoscopy or other imaging examination such as CT or MR, capable of detecting EGV; ‡The proportion of EGVB was calculated by dividing number of patients reported with EGVB by the number of confirmed EGV patients